Digestive and breast cancer patients managed during the first wave of COVID-19 pandemic: Short and middle term outcomes

Table 6 Characteristics of liver and pancreatic cancer and performed surgeries

n (%)	Pancreas, n = 6		Liver, n = 6
Histology	Adenocarcinoma	4 (66.7) [1DCC]	Tumour type	CR metastasis	6 (100.0)
	Neuroendocrine	2 (33.3)		Other	0
Resectability (NCCN classification)	Resectable	3 (50.0)	Pre-COVID Extent of resection	Minor	2 (33.3)
	Borderline resectable (vein)	2 (33.3)		Major	3 (50.0)
	Borderline resectable (artery)	0		Extra major	1 (16.7)
	Locally advanced	1 (16.7)
Preoperative biliary drainage	0		0
Previous COVID	0		0
Neoadjuvant therapy	Long-course Chemo	1 (16.7)	4 (57.14)
	Short-course Chemo		1 (14.3)
	Radiochemotherapy	1 (16.7)
CRITCON level	0	3 (50)	4 (66.7)
	1	1 (16.7)	2 (33.3)
	2	2 (33.3)
Operative approach	Open	6 (100)	5 (83.3)
	MIS		1 (16.7)
Resection margin status	R0	3 (50.0)	4 (66.6)
	R1	3 (50.0) [2 NE]	1 (16.7)
	Imaging complete	0	1 (16.7)
Final staging	IB	2 (33.3)
	IIB	2 (33.3) [1DCC]
	III	2 (33.3) [2 NE]

NE: Neuroendocrine tumour; DCC: Distal cholangiocarcinoma; Chemo: Chemotherapy; MIS: Minimally invasive surgery; R0: No microscopic disease at margin; R1: Microscopic disease at margin; R2: Macroscopic disease at margin.